GeneCentric Therapeutics acquires Select ImmunoGenomics

This article was originally published here

The acquisition provides the combined company with a comprehensive, integrated set of RNA-based solutions to enhance drug development by identifying the right patients for oncology drugs, improving response

The post GeneCentric Therapeutics acquires Select ImmunoGenomics appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply